A. Becker

1.5k total citations · 1 hit paper
42 papers, 988 citations indexed

About

A. Becker is a scholar working on Clinical Psychology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, A. Becker has authored 42 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Clinical Psychology, 16 papers in Organic Chemistry and 14 papers in Cellular and Molecular Neuroscience. Recurrent topics in A. Becker's work include Psychedelics and Drug Studies (19 papers), Chemical synthesis and alkaloids (14 papers) and Neurotransmitter Receptor Influence on Behavior (12 papers). A. Becker is often cited by papers focused on Psychedelics and Drug Studies (19 papers), Chemical synthesis and alkaloids (14 papers) and Neurotransmitter Receptor Influence on Behavior (12 papers). A. Becker collaborates with scholars based in Switzerland, Germany and Netherlands. A. Becker's co-authors include Matthias E. Liechti, Friederike Holze, Urs Duthaler, Anne Eckert, Nimmy Varghese, Christoph Saal, Karolina E. Kolaczynska, Aaron Klaiber, Laura Ley and Isabelle Straumann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Biophysical Journal and Neuropsychopharmacology.

In The Last Decade

A. Becker

36 papers receiving 963 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

2022 142 citations Friederike Holze, Laura Ley et al. Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Becker Switzerland	16	643	445	405	137	86	42	988
Agnete Dyssegaard Denmark	15	394 0.6×	274 0.6×	462 1.1×	230 1.7×	64 0.7×	32	912
F.X. Vollenweider Switzerland	9	443 0.7×	198 0.4×	353 0.9×	59 0.4×	43 0.5×	23	597
Theresa M. Carbonaro United States	11	864 1.3×	538 1.2×	429 1.1×	77 0.6×	168 2.0×	17	970
Nadia R. P. W. Hutten Netherlands	14	695 1.1×	385 0.9×	424 1.0×	54 0.4×	117 1.4×	25	868
Adelaida Morte Spain	14	556 0.9×	175 0.4×	281 0.7×	108 0.8×	249 2.9×	27	1.1k
Lee E. Dunlap United States	8	504 0.8×	296 0.7×	412 1.0×	142 1.0×	82 1.0×	12	697
Adam K. Klein United States	9	416 0.6×	271 0.6×	297 0.7×	77 0.6×	82 1.0×	16	518
Débora González Spain	11	668 1.0×	326 0.7×	353 0.9×	267 1.9×	231 2.7×	18	1.1k
Hanne D. Hansen Denmark	21	236 0.4×	202 0.5×	489 1.2×	342 2.5×	40 0.5×	63	1.3k
Jason Wallach United States	21	780 1.2×	367 0.8×	636 1.6×	216 1.6×	151 1.8×	32	1.2k

Countries citing papers authored by A. Becker

Since Specialization

Citations

This map shows the geographic impact of A. Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Becker more than expected).

Fields of papers citing papers by A. Becker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Becker. The network helps show where A. Becker may publish in the future.

Co-authorship network of co-authors of A. Becker

This figure shows the co-authorship network connecting the top 25 collaborators of A. Becker. A scholar is included among the top collaborators of A. Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Becker. A. Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hartmann, Matthias, Yasmin Schmid, A. Becker, et al.. (2025). The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. Journal of Psychopharmacology. 4126446288–4126446288.

Klaiber, Aaron, Laura Ley, A. Becker, et al.. (2025). Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. Clinical Pharmacokinetics. 64(10). 1495–1506.

Schmid, Yasmin, Felix Müller, A. Becker, et al.. (2025). Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults. JAMA Psychiatry. 82(6). 555–555. 4 indexed citations

Becker, A., Isabelle Straumann, Jan Thomann, et al.. (2025). Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial. Clinical Pharmacology & Therapeutics. 117(6). 1784–1792. 6 indexed citations

Müller, Felix, A. Becker, Laura Ley, et al.. (2025). Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med. 6(9). 100725–100725. 2 indexed citations

Vizeli, Patrick, Erich Studerus, Friederike Holze, et al.. (2024). Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants. Translational Psychiatry. 14(1). 357–357. 9 indexed citations

Straumann, Isabelle, et al.. (2024). Safety pharmacology of acute psilocybin administration in healthy participants. Neuroscience Applied. 3. 104060–104060. 9 indexed citations

Klaiber, Aaron, Yasmin Schmid, A. Becker, et al.. (2024). Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. Translational Psychiatry. 14(1). 395–395. 12 indexed citations

Müller, Lorenz, A. Becker, Aaron Klaiber, et al.. (2024). Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology. 50(6). 1008–1016. 3 indexed citations

10.

Ley, Laura, Isabelle Straumann, A. Becker, et al.. (2023). Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Neuroscience Applied. 2. 103377–103377.

11.

Ley, Laura, Friederike Holze, A. Becker, et al.. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 48(11). 1659–1667. 75 indexed citations

12.

Ley, Laura, Isabelle Straumann, A. Becker, et al.. (2023). Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Translational Psychiatry. 13(1). 172–172. 54 indexed citations

13.

Holze, Friederike, Laura Ley, Felix Müller, et al.. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 47(6). 1180–1187. 142 indexed citations breakdown →

14.

Schneider, Brooke C., Martin Brüne, Francesca Bohn, et al.. (2016). Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trial. BMC Psychiatry. 16(1). 51–51. 9 indexed citations

15.

Eisenacher, Sarah, Franziska Rausch, Daniela Mier, et al.. (2016). Bias against disconfirmatory evidence in the ‘at-risk mental state’ and during psychosis. Psychiatry Research. 238. 242–250. 23 indexed citations

16.

Englisch, Susanne, et al.. (2016). Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders. Journal of Clinical Psychopharmacology. 36(6). 597–607. 11 indexed citations

17.

Becker, Christoph, A. Becker, & Jens Pfeiffer. (2015). Health-related quality of life in patients with nasal prosthesis. Journal of Cranio-Maxillofacial Surgery. 44(1). 75–79. 20 indexed citations

18.

Saal, Christoph & A. Becker. (2013). Pharmaceutical salts: A summary on doses of salt formers from the Orange Book. European Journal of Pharmaceutical Sciences. 49(4). 614–623. 75 indexed citations

19.

Fackler-Schwalbe, I., et al.. (2004). Occlusion of central venous port catheters after simultaneous 24 h infusions of 5-fluorouracil and calcium-folinic acid in patients with gastrointestinal cancer. Wiener Medizinische Wochenschrift. 154(9-10). 182–185. 1 indexed citations

20.

Schmies, Georg, Beate Lüttenberg, Igor Chizhov, et al.. (2000). Sensory Rhodopsin II from the Haloalkaliphilic Natronobacterium pharaonis: Light-Activated Proton Transfer Reactions. Biophysical Journal. 78(2). 967–976. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact